Charles River Laboratories beats top-line and bottom-line estimates; updates FY26 outlook
Charles River Laboratories press release (CRL): Q3 Non-GAAP EPS of $3.09 beats by $0.12. Revenue of $982.7M (-1.7% Y/Y) beats by $22.34M. Organic revenue growth of 4.7%.